StockData
CorMedix Inc. logo

CorMedix Inc. (CRMD) income statement

CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$4.50−0.17 (-3.64%)

Close on Nov 18, 2026Market cap $350.75MP/E –Yield –

CorMedix Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
82.8%
Operating margin
47.0%
Net margin
40.5%
Return on equity, FY2025
66.6%

Financial strength

Current ratio
2.56
Debt to equity
–
Debt to assets
–
Cash to current liabilities
137.0%

Valuation

P/E ratio
–
Price to sales
0.76
Price to book
0.76
Dividend yield
–

See a number that looks wrong?